Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
147.24
-2.64 (-1.76%)
At close: Oct 22, 2026, 4:00 PM EDT
147.62
+0.38 (0.26%)
After-hours: Oct 22, 2026, 7:59 PM EDT
Merck & Co. Market Cap
Merck & Co. has a market cap or net worth of $363.27 billion as of October 22, 2026. It is the 38th most valuable company in the world and the 28th biggest in the United States. Its market cap has increased by 65.98% in one year.
Market Cap
363.27B
Enterprise Value
410.04B
1-Year Change
65.98%
Global Rank
Country Rank
#28 United States
Category
ChartMarket Cap Chart
Since December 1, 1998, Merck & Co.'s market cap has increased from $187.00B to $363.27B, an increase of 94.26%. That is a compound annual growth rate of 2.41%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 22, 2026 | 363.27B | 39.05% |
| Dec 31, 2025 | 261.26B | 3.82% |
| Dec 31, 2024 | 251.65B | -8.91% |
| Dec 29, 2023 | 276.26B | -1.79% |
| Dec 30, 2022 | 281.30B | 45.31% |
| Dec 31, 2021 | 193.59B | -6.46% |
| Dec 31, 2020 | 206.96B | -10.62% |
| Dec 31, 2019 | 231.56B | 16.54% |
| Dec 31, 2018 | 198.69B | 29.61% |
| Dec 29, 2017 | 153.30B | -5.55% |
| Dec 30, 2016 | 162.31B | 10.00% |
| Dec 31, 2015 | 147.55B | -8.86% |
| Dec 31, 2014 | 161.90B | 10.71% |
| Dec 31, 2013 | 146.24B | 17.50% |
| Dec 31, 2012 | 124.46B | 8.31% |
| Dec 30, 2011 | 114.91B | 3.49% |
| Dec 31, 2010 | 111.03B | 44.07% |
| Dec 31, 2009 | 77.07B | 19.91% |
| Dec 31, 2008 | 64.27B | -49.18% |
| Dec 31, 2007 | 126.48B | 33.62% |
| Dec 29, 2006 | 94.66B | 36.08% |
| Dec 30, 2005 | 69.56B | -2.41% |
| Dec 31, 2004 | 71.27B | -30.66% |
| Dec 31, 2003 | 102.79B | -19.14% |
| Dec 31, 2002 | 127.12B | -4.96% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 1.13T |
| Johnson & Johnson | 621.22B |
| AbbVie | 503.28B |
| Novartis AG | 292.31B |
| AstraZeneca | 262.05B |
| Amgen | 236.98B |
| Gilead Sciences | 190.42B |
| Novo Nordisk | 173.82B |